Tom

Dr Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academia, pharma, and regulators. In 2021 he was promoted to VP of Science and Technology and then to Chief Scientific Officer in 2023, with responsibility for all technical activities, including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.

Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.

Adrian

A seasoned business developer with extensive commercial experience in the life science sector, Adrian Rea joined CN Bio as the European Director of Sales in June 2022. He brings valuable experience in the 3D cell culture market from his most recent role at InSphero, where he was responsible for developing business opportunities in European and Asian markets. He was previously Sales Director at Enzo Life Sciences, where he managed the restructuring of the global distributor sales channels and expanding the European sales operations. Adrian graduated from the University of Glasgow and received his PhD in pharmacology from Glasgow Caledonian University. 

Joe

Joe Parisi is a Commercial Leader with 14 years’ experience in the life science sector. Joe joined CN Bio as the Americas Director of Sales in December 2023. He comes to CN Bio with valuable startup experience most recently at IsoPlexis and Purigen Biosystems, where he was responsible for building commercial opportunities across the US West. He was previously Sales Director at PhenomeX (now Bruker Cellular Analysis), where he managed the proteomics team in the US West focusing on capital equipment sales for single-cell functional analysis. Joe graduated from the University of Illinois Champaign-Urbana with a BSc in Molecular and Cellular Biology.

Emily

Dr Emily Richardson is a Lead Scientist in the R&D team at CN Bio. She joined the team in 2020 as a Senior Scientist and lead the development of the PhysioMimix® lung and lung-liver MPS models. Emily is highly experienced in the application of complex cell biology to drug discovery, having previously worked in cellular therapeutics in an industry setting and as a trained biochemist with specialty in molecular biology. She completed her PhD at the University of Leicester, using 3D cell culture to determine molecular mechanisms driving highly metastatic lung cancers. She now leads R&D projects within the CN Bio team revolving around toxicology in the liver and the lung MPS, as well as driving collaborative projects with various academic, industry and regulatory partners.

Anthony

Dr. Anthony Berger is CN Bio’s US-based Field Application Scientist, providing support for the PhysioMimix® Organ-on-Chip benchtop platform. Anthony has an extensive research background in 3D cell culture, biomaterials, and microfluidics, focusing on how the microenvironment influences cellular decision-making. He is a proponent of complex 3D in vitro models and desires to decrease the barrier to entry of these technologies. Anthony received his BS from Indiana University (US), PhD from the University of Wisconsin (US), and completed a postdoctoral fellowship at Temple University (US).

Sung

A seasoned life science professional with over 20 years of experience in product management, product marketing, and commercial leadership, Sung Lee joined CN Bio as a Director of Product Management in October 2024. He brings valuable experience in the assay kit market from his most recent role at Abcam, where he was the global lead as the Senior Product Director for the Assay Kits and Protein product portfolio. He has held various leadership roles at renowned companies like Abcam (Danaher Company), Epitomics (‘The Rabbit Monoclonal Company’), and Life Technologies (Thermo Fisher Scientific). Sung’s education background includes business certifications from Cambridge Judge Business School and Wharton Business School, and a degree in Molecular and Developmental Biology from the University of California, Santa Cruz.

Ovi

Dr Ovidiu Novac is a Senior Scientist at CN Bio and a knowledgeable organ-on-a-chip (OOC) expert. Ovi performed on several assay development projects as lead biological scientist, is a knowledgeable organ-on-a-chip (OOC) expert, and has experience in assessing drug induced liver injury in vitro. Ovi has a background in the developmental stage of pharmaceutical and dermatological formulations and their performance assessment on human skin tissue ex vivo (topical and transdermal), and for strategic planning for further evaluation. During time spent in the pharma industry he contributed to delivering high quality results used for marketing purposes and in regulatory submissions. Ovi holds a BSc in biomaterials and prosthetic technologies and a PhD in chemistry and has been involved in research on controlled drug delivery systems since 2006.